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Lymphatic precollectors contain a novel, specialized
subpopulation of podoplanin low, CCL27-expressing lymphatic
endothelial cells
Abstract
Expression of the lymphoendothelial marker membrane mucoprotein podoplanin (podo) distinguishes
endothelial cells of both blood and lymphatic lineages. We have previously discovered two distinct
subpopulations of lymphatic endothelial cells (LECs) in human skin that were defined by their cell
surface densities of podoplanin and were designated LEC podo-low and LEC podo-high. LEC podo-low
is restricted to lymphatic precollector vessels that originate from initial LEC podo-high-containing
lymphatic capillaries and selectively express several pro-inflammatory factors. In addition to the
chemokine receptor protein Duffy blood group antigen receptor for chemokines, these factors include
the constitutively expressed chemokine CCL27, which is responsible for the accumulation of pathogenic
CCR10+ T lymphocytes in human inflammatory skin diseases. In this study, we report that CCR10+ T
cells accumulate preferentially both around and within CCL27+ LEC podo-low precollector vessels in
skin biopsies of human inflammatory disease. In transmigration assays, isolated CCR10+ T lymphocytes
are chemotactically attracted by LEC podo-low in a CCL27-dependent fashion, but not by LEC
podo-high. These observations indicate that LEC podo-low-containing precollector vessels constitute a
specialized segment of the initial lymphatic microvasculature, and we hypothesize that these LEC
podo-low-containing vessels are involved in the trafficking of CCR10+ T cells during skin
inflammation.
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Expression of the lymphoendothelial marker membrane
mucoprotein podoplanin (podo) distinguishes endothe-
lial cells of both blood and lymphatic lineages. We have
previously discovered two distinct subpopulations of lym-
phatic endothelial cells (LECs) in human skin that were
defined by their cell surface densities of podoplanin and
were designated LECpodo-low and LECpodo-high. LECpodo-low
is restricted to lymphatic precollector vessels that origi-
nate from initial LECpodo-high-containing lymphatic capil-
laries and selectively express several pro-inflammatory
factors. In addition to the chemokine receptor protein
Duffybloodgroupantigenreceptor for chemokines, these
factors include the constitutively expressed chemokine
CCL27, which is responsible for the accumulation of
pathogenic CCR10 T lymphocytes in human inflamma-
tory skin diseases. In this study, we report that CCR10 T
cells accumulate preferentially both around and within
CCL27 LECpodo-lowprecollector vessels in skinbiopsies of
human inflammatory disease. In transmigration assays,
isolated CCR10 T lymphocytes are chemotactically at-
tracted by LECpodo-low in a CCL27-dependent fashion, but
not by LECpodo-high. These observations indicate that
LECpodo-low-containing precollector vessels constitute a
specialized segment of the initial lymphatic microvascula-
ture, and we hypothesize that these LECpodo-low-con-
taining vessels are involved in the trafficking of
CCR10 T cells during skin inflammation. (Am J Pathol
2008, 173:1202–1209; DOI: 10.2353/ajpath.2008.080101)
The dermal lymphatic microvasculature drains interstitial
fluid and passenger cells into lymph nodes. Its complex
microanatomy was previously cartographed by tracer in-
jections and found to consist of superficial initial, blind-
ending capillaries that are linked via precollectors to
deep collecting vessels.1 It is commonly believed that
initial capillaries constitute the principal site of lymphatic
function and that they provide exit routes for cells from
the interstitial compartment, eg, antigen-presenting cells,
in normal tissues and “spent” pathogenic lymphocytes in
inflammation. By contrast, the subsequent precollectors
and collectors are considered as passive sewer systems.
However, there is no definite experimental proof for this
naı¨ve concept. A possible clue to potentially different
functions of these vascular segments could be provided
by distinct properties of endothelial cells in each com-
partment, but also, no information exists about lymphatic
endothelial cell (LEC) heterogeneity. Here, we report the
existence of two distinct subpopulations of LECs that are
distinguished by their differential expression of the gen-
eral LEC marker podoplanin and other molecules, such
as pro-inflammatory chemokines. We demonstrate that
these LEC subpopulations strictly associate with initial
lymphatic capillaries and precollectors, respectively, and
we examine their potential functional diversity in inflam-
matory skin diseases.
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Materials and Methods
Isolation of Endothelial Cells
Blood vascular endothelial cells (BECs) and LECs were
isolated ex vivo from dermatome skin sheets from cos-
metic breast surgery specimens of healthy females, in a
two step protocol using mechanical and enzymatic dis-
sociation, followed by fluorescence-activated cell sorting
(FACStar Plus; BD Biosciences, Franklin Lakes, NJ) using
CD45 antibodies for gating and CD31 and podoplanin
antibodies for separation as reported previously.2,3
LECpodo-low and LECpodo-high were purified by fluores-
cence-activated cell sorting separation of the total LEC
fraction by increasing the resolution of the podoplanin
channel. The collected cells were lysed for RNA isolation
or immobilized on slides by cytospin (Cytospin 3; Dako
Cytomation, Glostrup, Denmark) or taken into tissue cul-
ture. The study complied with the Declaration of Helsinki
and was as approved by the local ethics committee
(permit no. 449/2001).
Antibodies
We used the IgG fraction of a rabbit polyclonal anti-
podoplanin and of the corresponding preimmune se-
rum.3,4 The other reagents were FITC-conjugated mono-
clonal anti-CD31 (catalog no. 555445; BD Biosciences
Pharmingen, Franklin Lakes, NJ), RPE-Cy5.1-conjugated
mouse monoclonal anti-CD45 (catalog no. PM IM2653;
Beckman Coulter, Inc., Fullerton, CA), mouse clone 2C3
anti-Duffy blood group antigen receptor for chemokines
(DARC)/Fy (kindly provided by Dr. Ives Colin; INSERM,
Institute National de Transfusion Sanguine, Paris5,6),
mouse monoclonal anti-CCL27 (catalog no. MAB3761;
R&D Systems, Minneapolis, MN), neutralizing rat anti-
CCL27 antibody (clone 68623; catalog no. MAB725; R&D
Systems), rat IgG-Isotype control (catalog no. ab37361;
Abcam, Cambridge, UK), mouse monoclonal anti-CCL21
(catalog no. AF366; R&D Systems), goat polyclonal anti-
CCR10 (catalog no. NB 100-707; Novus Biologicals,
Littleton, CO), rat monoclonal anti-human CLA antibody
(catalog no. 55946; BD Biosciences Pharmingen), mouse
monoclonal anti-CD31 (catalog no. M0823; Dako Cyto-
mation), and phycoerythin-conjugated mouse monoclo-
nal anti-CD3 (catalog no. 345765; Becton Dickinson) an-
tibodies. Secondary agents were phycoerythin-
conjugated donkey polyclonal anti-rabbit IgG (WG,
catalog no. 711-116-152; Jackson ImmunoResearch
Laboratories, Inc., West Grove, PA), Alexa Fluor 594-
conjugated goat anti-mouse and Alexa Fluor 488- and
350-conjugated goat anti-rabbit (1 g/ml; nos. catalog
nos. A-11020, A-11034 and A-11046; Molecular Probes,
Inc., Eugene, OR), and 10 nm gold-labeled goat anti-
rabbit (catalog no. RPN421; Amersham Biosciences,
Uppsala, Sweden) antibodies.
RNA Analysis
Isolation of total RNA, generation of cRNA, and DNA chip
hybridzation were performed as described previously.4
DNA chip hybridzation was performed on GeneChip
U133A (Affymetrix, Inc., Santa Clara, CA). Raw and pro-
cessed data were deposited at ArrayExpress (accession
no. E-TABM-227). DNA chip raw data were normalized to
a subset of 10 housekeeping genes using MAS 5.0 soft-
ware and exported as spreadsheets. Considering the
sample size of n  2, only postnormalized probe set
values tagged as “present” were accepted. Ratios of
values of LECpodo-low and LECpodo-high sample pairs de-
riving from each patient were calculated. Both ratios were
averaged, and a threshold of differential induction of
fivefold was applied. Finally, bibliographic search on
PubMed database for co-occurrence of the gene name
and the keywords “skin” and “chemokine” defined a se-
lected list of eight genes induced in LECpodo-low versus
LECpodo-high. The two housekeeping genes in nonquan-
titative RT-PCR were breakpoint cluster region and
 2-microglobulin, as described previously.3 In addition,
early passage cultures of LECpodo-low and LECpodo-high
were subjected to quantitative real-time PCR (Applied
Biosystems, Foster City, CA) for relative podoplanin
mRNA quantification using Ct.
Morphological Analysis
For electron microscopy, human skin was fixed in 4%
PFA and 0.1% glutaraldehyde and embedded in Lowic-
ryl-K4M, and sections were immunolabeled with 20 g/ml
anti-podoplanin antibody, followed by 10 nm goat anti-
rabbit gold conjugate (final concentration, 1:10). The
number of gold particles bound to 500 m of LEC
plasma membranes were counted and expressed as
number of gold particles per 1 m. Lymphatic capillaries
were identified by their expression of podoplanin, the
absence of continuous basement membranes, and lack
of erythrocytes in their lumen.
For reconstruction of lymphatic vessels in three dimen-
sions, double immunofluorescence was performed on 100
m cryostat sections of tissue samples that were fixed in 4%
PFA for 1.5 hours at 22°C, immersed into 30% sucrose at
4°C overnight, and frozen in liquid nitrogen.7 The sections
were immunolabeled with antibodies against podoplanin
(2.8 g/ml) and CCL27 (2.5 g/ml). After extensive wash-
ing, they were postfixed in 4% paraformaldehyde for 10
minutes at 22°C and permeabilized with 0.3% Triton X-100
for 60 minutes. Primary antibodies were incubated for 3
days at 22°C, and secondary antibodies were incubated for
6 hours. Sections were analyzed by confocal laser scanning
microscopy using a Zeiss LSM 510 (Carl Zeiss, Jena, Ger-
many). Three-dimensional visualization was realized in a
program in JAVA, based on the Visualization Toolkit 5.0
(Kitware, Clifton Park, NY; http://www.vtk.org). Negative
controls omitting the first antibodies consistently gave neg-
ative results, as did incubation with nonimmune sera (data
not shown).
Immunofluorescence labeling was performed on 2-m
paraffin sections of formaldehyde-fixed human tissues.
After antigen retrieval by microwaving twice for 5 minutes
in 0.01 mol/L citrate buffer, pH 6, primary antibodies were
combined with antibodies conjugated to fluorescent dyes
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for double or triple staining.8 Images were captured with
the Axiophot epifluorescence system (Zeiss). We com-
bined immunolabeling by antibodies toward podoplanin
with those specific for DARC (final concentration 20 g/
ml), CCL21 (15 g/ml), CCR10 (4 g/ml), and CCL27. For
quantification of the distribution of CCR10 in the
perivascular stroma, the perilymphatic area was divided
into concentric rings of incremental 10-m radiuses
(R1–3) measured from the vessel’s outer surface, and
CCR10 cells were counted in each segment and nor-
malized to 1000 m2. Also, the number of CCR10 cells
was determined in the vascular lumen.
Cell Culture
Culturing of human LEC subpopulations was performed on 10
g/ml fibronectin-coated dishes (catalog no. 354008; BD Bio-
sciences) in EGM-2MV complete growth medium (catalog no.
CC-3202; Cambrex, Inc., East Rutherford, NJ). Cells were
detached by 1 trypsin-EDTA (catalog no. 25300-05; Invitro-
gen, Carlsbad, CA), lysed in SDS sample buffer, and analyzed
by reduced gel electrophoresis and Western blotting. For im-
munofluorescence, endothelial cells were fixed for 15 minutes
at 22°C in 4% paraformaldehyde. Nuclei were stained with 10
g/ml 4,6-diamidino-2-phenylindole hydrochloride (SERVA
GmbH, Heidelberg, Germany). The concentration of CCL27 in
tissue culture supernatants was determined by ELISA (R&D
Systems).
Transmigation Assays
BECs, LECpodo-low, and LECpodo-high were seeded onto
the bottom of transwell dishes with polycarbonate mem-
brane inserts with 5-m pores (catalog no. 3421; Costar,
Cambridge, MA).9 CD3 CCR10 human peripheral
blood T lymphocytes were purified from pooled human
blood samples by fluorescence-activated cell sorting,
labeled with CellTracker (2 g/ml CellTracker green CM-
FDA; catalog no. C2925; Invitrogen), and resuspended in
100 l RPMI with 10% fetal calf serum; and 1  105 cells
were added into the top chamber of each insert. After 4
hours, the trans-migrated cells in the lower chamber were
collected by cytospinning onto microscope slides and
counted in a fluorescence microscope. Fixed cells were
additionally immunostained with 10 g/ml anti-CLA anti-
body. In some experiments, 10 g/ml neutralizing mono-
clonal rat anti-CCL27 antibody was added into the bot-
tom chamber. As control, isotype matched irrelevant rat
IgG was used in the same concentration in parallel
experiments.
Statistical Analysis
All quantitative experiments were performed at least in tripli-
cate (RT-PCR, numbers of immunogold particles per micro-
meter of LEC cell membrane representing podoplanin, capil-
lary densities in histological sections, localization of CCR10
T lymphocytes in relation to lymphatic vessels in situ, and
CCR10 T-lymphocyte transmigration assays), and the results
were subjected to the two-sided Student’s t-test.
Results
Differential Expression of Podoplanin in Two
Distinct LEC Subpopulations
The fluorescence-activated cell sorting pattern of isolated
dermal microvascular CD45CD31Podoplanin LECs
and CD45CD31Podoplanin BECs has previously
suggested the presence of two overlapping LEC sub-
populations that varied in their surface expression of
podoplanin.2 Here, we have isolated these two LEC co-
horts, and designated them as LECpodo-low and LECpodo-high
(Figure 1A). The distinctly different levels of podoplanin
expression of LECpodo-low and LECpodo-high were con-
firmed by indirect immunofluorescence in ex vivo cytospin
preparations (Figure 1B), and their lymphatic phenotype
was supported by nonquantitative RT-PCR for the estab-
lished LEC markers LYVE-1, Prox1, and the pan-endo-
thelial marker von Willebrand factor (Figure 1, C and F). In
cell culture, small amounts of podoplanin protein were
detected by Western blotting in LECpodo-low that, how-
ever, remained abundant in LECpodo-high (Figure 1 D).
This was also confirmed at the level of mRNA by quanti-
tative RT-PCR (Figure 1E). In later passages, the expres-
sion of podoplanin in LECpodo-low increased toward the
levels of LECpodo-high, whereas the expression of the
LECpodo-low typic chemokine CCL27 (Figure 1G) was lost
after the second passage (data not shown).
Restricted Localization of LECpodo-low in
Lymphatic Precollectors
To identify additional markers for the precise localization of
LECpodo-low and to gain insight into the LECpodo-low’s distinct
phenotype in normal and particularly in inflamed tissues, a
DNA chip analysis was performed in a shotgun approach. We
purified RNA from freshly isolated LECpodo-low, LECpodo-high,
total LECs, and total BECs2,3 that were isolated from the
dermis of two patients without skin disease. In Affymetrix
arrays, we identified 107 genes that were amplified by at
least fivefold in LECpodo-low. Of these, eight were associ-
ated with inflammation (Table 1) and included members
of the chemokine/chemokine receptor family, such as
Ccl27, Cxcl12, Cxcl14, and Darc. In addition, LECpodo-low
overexpressed E-selectin, components of the major his-
tocompatibility complex type II (MHC II), and placental
growth factor. By contrast, LECpodo-high significantly over-
expressed Ccl21. The chemokine CCL27 was expressed
in cultured LECpodo-low, but not in LECpodo-high (Figure
1G), and released into cell culture media in a concentra-
tion 1 ng/ml.
For immunohistochemical colocalization of LECpodo-low
with podoplanin, we selected CCL27 (CTACK),10 an es-
tablished pathogenic chemokine in dermal inflammatory
diseases that was robustly expressed by LECpodo-low, but
not by LECpodo-high, and the chemokine binding protein
DARC,11 taking advantage of its nondiffusibility as a
membrane protein. The results of these colocalization
studies indicated that LECpodo-low were restricted exclu-
sively to a distinct segment of the lymphatic vasculature,
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separate from LECpodo-high vessels (Figure 2A). Within
single lymphatic vessels, there was consistently no inter-
mixing of the two LEC subpopulations. Immunoelectron
microscopy also confirmed the at least fourfold different
podoplanin content on the plasma membrane surface of
LECpodo-low and LECpodo-high (Figure 2B).
To determine the topographic relation of LECpodo-low
and LECpodo-high in the lymphatic vasculature, we recon-
structed in three dimensions consecutive confocal im-
ages of 100-m-thick sections of normal human skin that
were double labeled for podoplanin and CCL27 or DARC.
The images obtained demonstrated that LECpodo-low were
restricted to precollector vessels that branch out of
LECpodo-high initial lymphatic capillaries (Figure 2C). The
latter exclusively expressed CCL2112 and large amounts
of podoplanin, in contrast to LECpodo-low vessels that
were immunolabeled for CCL27 (Figure 2D). This indi-
cated that LECpodo-low were restricted to lymphatic pre-
collectors that directly originate from canonical initial
LECpodo-high lymphatic capillaries, and that the LEC sub-
Figure 1. Ex vivo isolation, in vitro expansion, and
characterization of LECpodo-low and LECpodo-high. A:
BECs, LECs, LECpodo-low, and LECpodo-high were sep-
arated by fluorescence-activated cell sorting ex vivo
from CD45-gated human dermatome skin cell sus-
pensions, using CD31 and podoplanin antibodies.
CD31 podoplanin BECs (top left), CD31 podo-
planin total LECs (top right, the red bar separates
two overlapping subpopulations), CD31 podo-
planinhigh LECs (bottom left, red circle), and
CD31podoplaninlow LECs (bottom right, red circle)
are resolved. B: Cytospin preparations of ex vivo
isolated LECpodo-low and LECpodo-high show differen-
tial podoplanin expression by immunofluorescence.
C:Nonquantitative RT-PCR reveals the expression of
the LEC marker genes Prox1 and LYVE-1, and the
pan-endothelial marker vonWillebrand factor (vWF)
in LECpodo-low and LECpodo-high.D:After two rounds
of expansion in tissue culture of LECpodo-low and
LECpodo-high, the differential expression of podopla-
nin protein is confirmed by immunoblotting and re-
lated to CD31 expression. E: Quantitative RT-PCR
confirmed the different levels of podoplanin mRNA
expression (P 0.001). F: Prox1 is stably expressed
in cultured LECpodo-low and more abundant in
LECpodo-high, whereas expression of the LECpodo-low
specific marker CCL27, indicated here by red im-
munofluorescence in cultured LECpodo-low (G,
left) is lost after the third passage in cell culture.
LECpodo-high fail to express CCL27 (G, right). All
bars  10 m.
Table 1. Inflammation-Associated Genes in LECpodo-low
Genes Podo-low Podo-high Total LEC Total BEC Podo-low/high
Markers used in this study
Ccl27 (chemokine CC motif ligand 27, cutaneous T
cell-attracting chemokine/Ctack)
1293.3 176.4 343.6 341.7 7.3
Darc 2545.8 480.2 1738.9 3674.5 5.3
Ccl21 (chemokine CC motif ligand 21, secondary
lymphoid tissue chemokine/Slc)
66.1 2725.4 2828.6 20.8 0.024
Markers not used in this study
Cxcl14 (chemokine CXC motif ligand 14. breast and
kidney/Brak)
6999.0 902.5 679.2 1105.6 7.8
Cxcl12 (chemokine CXC motif ligand 12. stromal
cell-derived factor 1/Sdf1)
1592.3 124.5 100.8 179.8 12.8
E-selectin (endothelial adhesion molecule, Sele) 3201.6 821.6 2828.6 5365.8 3.9
Major histocompatibility complex type II  (Cd74) 2045.2 471.3 884.0 3561.0 4.3
Major histocompatibility complex type II  DPB1
(Hla-dpb1)
2461.2 384.9 1354.9 4207.0 6.4
Plf (placental growth factor) 8267.6 775.3 507.8 788.3 10.7
Numbers indicate normalized fluorescence signal intensities for LECpodo-low, LECpodo-high, total LEC, and total BEC determined by Affymetrix DNA
chip analysis.4 Fold ratios between LECpodo-low and LECpodo-high are in the right column.
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populations expressed the same molecular signatures
discovered also in situ as seen before in isolated cell. A
similar compartmentalization of the lymphatic microvas-
culature with distinct segregation of LECpodo-high- and
LECpodo-low-containing segments was found in 6 samples
of normal skin, 15 cases of chronic dermal inflammatory
diseases, and in sporadic cases of renal transplant re-
jection (Figure 3A) and pulmonary disease (Figure 3B).
Increased Dermal Lymphatic Microvascular
Density in Inflammatory Skin Diseases
Lymphatic microvessel densities were determined in all
samples of normal and inflammatory skin, using podopla-
nin and CCL27 and/or DARC as immunohistochemical
markers. We observed that the overall lymphatic vessel
density increased threefold in chronic skin inflammation
Figure 2. Segmentation of the dermal lymphatic
microvasculature into LECpodo-low precollectors and
LECpodo-high initial lymphatic capillaries, revealed by
expression of distinct marker proteins. A: Localiza-
tion of DARC (left, red), podoplanin (middle,
green), and a merged picture with 4,6-diamidino-
2-phenylindole hydrochloride nuclear staining
(right, blue). Endothelial cells of the LECpodo-low
DARC type are restricted to a small vessel and do
not intermix with the larger LECpodo-high DARC
vessel. B: Immunoelectron microscopy supports the
differential expression of podoplanin on the luminal
cell surfaces of both LEC subpopulations. The den-
sity of gold particles that indicate podoplanin differ
three- to fourfold (P  0.05). C: Three-dimensional
reconstitution of the initial lymphatic microvessels in
human skin resolved by confocal laser scanning mi-
croscopy and subsequent three-dimensional recon-
struction of 100-m-thick sections, using antibodies
specific for podoplanin (green) andCCL27 (red). The
LECpodo-low indicators CCL27 and podoplaninlow are
restricted to a distinct vessel (Low) that branches out
of a larger, LECpodo-high CCL27 initial lymphatic
capillary (High). Merged versions of rotated presen-
tations of the anastomosing vessels are shownon the
left, and single channels on the right. D: Triple
immunofluorescence showing coexpression of high
levels of podoplanin (blue) with CCL21 (red) in
LECpodo-high (High) and of lower levels of podopla-
nin with CCL27 (green) in LECpodo-low (Low). Merge
of channels is on the bottom panel. Bars 10 m
in A, C, and D. Magnification: 70,000 (D).
Figure 3. Segregation of LECpodo-low and
LECpodo-high vessels in human kidney trans-
plant rejection (A) and chronic bronchiolitis
(B). Sections are immunolabeled with anti-
bodies specific for podoplanin (green, left)
and DARC (red, middle), and merged (right).
DARC expression is restricted to vessels con-
taining LECpodo-low (Low) and absent from
those containing LECpodo-high (High). Nuclear
4,6-diamidino-2-phenylindole hydrochloride
stain is blue. Bar  10 m.
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over normal controls and that the relative proportion be-
tween LECpodo-high lymphatic capillaries and LECpodo-low
precollectors remained constant. Blood capillaries that
were identified by expression of DARC endothelial cells
and erythrocytes were 50 times more abundant than
LECpodo-low and seven times more abundant than
LECpodo-high microvessels in normal skin and in all dis-
ease entities studied (Figure 4A).
Association of LECpodo-low Precollectors with
CCR10 T Lymphocytes in Inflammatory Skin
Diseases
It is established that in chronic inflammatory skin dis-
eases, the CCL27 receptor CCR10 on CLA pathogenic
T lymphocytes mediates homing to the dermis.13 In nor-
mal human skin, few sporadic CCR10 T lymphocytes
were found in the dermis, without significant relation to
microvessels (data not shown). By contrast, CCR10
inflammatory infiltrates in human skin samples of psoria-
sis (n  7), eczema (n  7), and chronic atrophic acro-
dermatitis (n  1) that constitute almost all lymphocytes
in these tissues were centered around CCL27-express-
ing LECpodo-low, as visualized by triple immunofluores-
cence (Figure 4B). Quantification of the density of the
CCR10 T lymphocytes supported this view, with almost
threefold higher densities around LECpodo-low-containing
precollectors than LECpodo-high initial capillaries. CCR10
T lymphocytes were found within the precollector’s lumen
but not in that of initial capillaries (Figure 4C).
Chemotactic Attraction of CCR10 T Cells by
LECpodo-low in Vitro
LECpodo-low, but not LECpodo-high expressed (Figure 1G)
and secreted small amounts of CCL27 (1 ng/ml) into the
medium. This raised the possibility to test whether or not
CCL27 LECpodo-low could attract CCR10 T lympho-
cytes also in vitro, as suggested by the immunohistolog-
ical in vivo results described above. Isolated LECpodo-low,
LECpodo-high, or BECs not later than in passage 2 were
grown to confluency in the lower compartments of trans-
Figure 4. Association of CCR10 T lymphocytes
with LECpodo-low-containing lymphatic precol-
lector vessels. A: Determination of the blood
and lymphatic microvessel densities in normal
(n  14) and inflamed human skin samples
(n  15) expressed as percentage of the total
vessel number counted (all P values 0.001;
error bars are SD). The ratio of vessel densities
remain constant in normal and inflamed skin. B:
Sections of a case with atopic dermatitis are
immunolabeled for the localization of CCL27
(top left, green), podoplanin (bottom left,
blue), and CCR10 (top right, red) and a merged
picture on the bottom right. CCL27 and podo-
planin differentially mark a LECpodo-high initial
lymphatic capillary (High) and a LECpodo-low
precollector (Low). CCR10 is expressed in in-
flammatory cells that are centered around the
precollector, and it is also expressed in small
amounts in LECpodo-low (Low). Bar  20 m. C:
Histogram showing the preferential accumulation of
CCR10 T lymphocytes around LECpodo-low precol-
lectors (dark green columns) and LECpodo-high
lymphatic capillaries (light green columns) and
in the vascular lumen (Lum). R1, R2, and R3
indicate concentric perivascular areas with in-
creasing radius (10 m) in which the quantita-
tion is performed. T lymphocytes are encoun-
tered up to three times more frequently around
LECpodo-low precollectors than around
LECpodo-high lymphatic capillaries (all P values
0.05; error bars  SD) and are found exclu-
sively within the lumina of LECpodo-low prec-
ollectors (Lum). D: Chemotactic transmigra-
tion assay of isolated human CCR10 CLA
CD3 T lymphocytes toward LECpodo-low
(dark green columns), LECpodo-high (light
green column), and BECs (red column) grown
in the lower compartment of Transwell cham-
bers. Transmigration of T lymphocytes is ob-
served toward LECpodo-low and is reduced by a
blocking antibody against CCL27 (Blocking
IgG, dark green column, red-shaded) but not
by a control IgG (Control, dark green col-
umn). Attraction by LECpodo-high and BECs are
considered as baseline values (all P values
0.05; error bars  SD).
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migration chambers, and CCR10 CD4 CLA T lym-
phocytes that were purified from human peripheral blood
were added to the upper chambers. Staining with anti-
CLA antibody showed that these T lymphocytes were
statistically significantly (P  0.05) more attracted by
LECpodo-low than by LECpodo-high or BECs. Addition of
anti-CCL27 antibody with established specific inhibitory
activity13 into the lower Transwell chamber reduced the
chemoattractive capacity of LECpodo-low to baseline lev-
els (Figure 4D).
Discussion
As points of entrance to their journey toward the local
lymph node and eventually into the venous blood stream,
passenger cells access the lymphatic vasculature that is
organized in blind ending, initial capillaries, precollec-
tors, and collectors. Here, we provide evidence that spe-
cialized lymphatic endothelial cells with distinct gene
expression signatures constitute initial capillaries and
precollectors. Notably, the expression of pro-inflamma-
tory chemokines is restricted to different lymphovascular
segments, and we present arguments that this could be
of relevance in inflammatory processes.
The major novel finding in this report is that initial
lymphatic capillaries and precollectors are endowed with
two distinctly different subpopulations of endothelial
cells. LEC heterogeneity was initially discovered by virtue
of the differential expression of the LEC-specific mem-
brane sialomucin podoplanin, and was extended further
to several other significant differences in gene expres-
sion, including characteristic gene expression of different
sets of chemokines and their receptors, suggesting po-
tentially different functions in normal tissues and in inflam-
matory processes. For example, LECpodo-low in precollec-
tors highly up-regulated CCL27, whereas CCL21 was
characteristically expressed by LECpodo-high in initial cap-
illaries. Previous work has raised the possibility that po-
doplanin is involved in the generation of chemotactic
gradients around initial capillaries, because CCL21 that
attracts CCR7 dendritic cells and T lymphocytes14 av-
idly bound to podoplanin and complexes were shed from
the surfaces of LEC.15 Recently, experimental evidence
was provided that the interaction of CCL21/CCR7 is in-
volved in clearing sporadic CCR7 cells from normal
skin.16
The discovery that LECpodo-low in lymphatic precollec-
tors produce CCL27 raised the possibility that this vas-
cular segment could be involved in trafficking of patho-
genic CCR10 T cells.13 These lymphocytes are the
principal pathogenic effector cells in inflammatory skin
diseases and in graft-versus-host reactions,17 constitut-
ing 	95% of the inflammatory infiltrate. Their import route
was recently mapped out in detail: CCL27 is produced by
inflammatory chemokine-activated epidermal keratino-
cytes and diffuses toward blood microvessels.13 There, it
is presented at the vascular lumen to attract circulating
CCR10 T lymphocytes and to initiate their emigration
into the stroma. The indispensable role of CCL27 in this
process was demonstrated by abrogation of experimental
murine dermatitis by neutralizing CCL27 antibodies.13,18
These results on the CCL27-driven mechanisms of lym-
phocyte entrance into the site of inflammation then raise
the question of what the role of CCL27 secreting LECpodo-low in
lymphatic precollectors could be. We provide arguments
that this segment of the lymphatic microvasculature
could serve as exit route for CCR10CLA T cells toward
the regional lymph node. First, this view is based on a
quantitative immunohistological analysis of 15 cases of
human inflammatory skin disease that shows a significant
selective recruitment of CCR10CLA T lymphocytes
around precollectors and within their lumen, in contrast to
initial capillaries. Second, in vitro transmigration assays
using cultured LECpodo-low indicate that CCL27 secreted
by these cells into the medium drives the transmigration
of isolated human CCR10CLA T cells. The efficiency of
precollectors as potential exit gate for lymphocytes could
be further enhanced by the selective presentation of
endothelial adhesion proteins on LECpodo-low, such as
E-selectin, that specifically interacts with CLA on the
surface of pathogenic CCR10 T lymphocytes.19 Intrigu-
ingly, also cutaneous T-cell lymphoma expresses
CCR10, and it remains to be determined whether any
interaction with LECpodo-low occurs and is related to their
dissemination.20
Expression of CCR10 was observed not only in T lym-
phocytes but also in LECpodo-low in inflamed tissues (Fig-
ure 4) and was detected in cultured LECs after exposure
to TNF in vitro,21 suggesting an autocrine regulatory
system that requires further elucidation. Also, the func-
tional significance of other gene products expressed
preferentially by LECpodo-low, such as CXCL12 and
CXCL14, remains to be investigated.
Synoptically, our findings establish that distinct sub-
populations of LECs are defined by their expression of
podoplanin and distinct patterns of chemokines. We fur-
ther show that these LEC subtypes constitute different
segments of the initial lymphatic vasculature. These re-
sults dovetail into the recent findings that the CD31-
containing interendothelial cell junctions of initial lym-
phatic capillaries differ from those in precollectors.22
Finally, our results raise the possibility that the LECpodo-low-
containing precollector segment of the lymphatic vascu-
lature is involved in the trafficking of pathogenic CCR10
T lymphocytes in inflamed tissues.
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